Startseite » Experimental medicine » Experimental pathology

Experimentelle Pathologie

Research focus

The experimental pathology deals with the phenotypic manifestations of diseases and their histological and molecular genetic correlates. Tumour diseases in particular are to be characterised at the molecular genetic level and the increasing knowledge about the molecular properties of organ tumours or metastases is to be used to improve diagnostics and therapy. Thus, attempts are being made to find markers and/or gene sequences on the basis of removed surgical or endoscopic tissue that allow conclusions to be drawn about the response of a tumour to therapy. All scientific investigations aim to develop new forms of diagnosis and treatment. In this way, the treatment options for many tumour diseases could already be specified – according to the individual situation.

Prostate carcinomas

Label-free digital pathology in cooperation with biophysics in PRODI

The aim of this study is to establish a label-free digital pathology with IR imaging for a fast, reliable and accurate diagnosis of prostate cancer. This method is based on spectral IR imaging of prostate tissue obtained during transurethral resection/laser enucleation of the prostate (TUR-P/TULEP). After the initial training phase, label-free digital histopathology will be applied to prostate tissue obtained during a punch biopsy for suspected prostate cancer.

ColoPredict Plus 2.0 Register study

Retrospective and prospective recording of the role of MSI and KRAS for the prognosis of stage I to III colon cancer; identification of a marker panel for the therapy of CRC.

The Colopredict Plus Registry will retrospectively and prospectively enrol patients with stage I to III colon cancer. The primary objective of the study is to determine the role of microsatellite instability (MSI) in combination with a KRAS mutation in the prognosis of stage II colon cancer without clinical risk factors. For this purpose, MSI and KRAS will be determined in tumour tissue samples of the recruited patients and clinical and histopathological data of the patients will be documented in parallel. The primary target parameter is relapse-free survival after 5 years (combined endpoint of relapse and death from any cause).

Method development

FTIR / Raman spectroscopy

Contact & Employees

Contact for scientific enquiries

Institute of Pathology
Professor  Dr. med. Andrea  Tannapfel
Bürkle-de-la-Camp-Platz 1
44789  Bochum
Phone:  +49 234 302 4800
Fax:  +49 234 302 4899

Pathology at RUB


Dr. med. C. Sternemann
Dr. med. D.-M. Zucha
Dr. med. I. Stricker

Dr. rer. nat. J. Christmann
Dr. rer. nat. B. Flott-Rahmel
Dr. rer. nat. J. Keller
Dr. rer. nat. B. Verdoot     
S. Wisser M.Sc.
V. Obst
P. Kailweit


Here you will find current publications:


For doctoral theses please contact

Dr. rer. nat. B. Flott-Rahmel